When navigating the complexities of hematologic tumors—including leukemia, lymphoma, and multiple myeloma—patients and our families seek expertise that combines innovation, precision, and compassionate care. GoBroad Healthcare Group (GHG), a pioneer in China’s research-oriented hospital model, has emerged as a trusted leader in diagnosing and treating these intricate blood-related cancers. With a focus on integrating cutting-edge technology, personalized treatment strategies, and multidisciplinary collaboration, we are changing outcomes for patients with hematologic tumors, even in the most challenging cases.

A Legacy of Expertise in Hematologic Tumor Care
Founded on the principle of prioritizing patient needs, we has established ourselves as a hub for advanced care in hematologic diseases. We specializes in managing severe and complex conditions, from acute leukemias to aggressive lymphomas and treatment-resistant multiple myeloma. By combining state-of-the-art diagnostics with a deep understanding of molecular biology, Our team of oncologists, hematologists, and researchers delivers tailored solutions that address the unique genetic and clinical profiles of each patient. Our commitment to innovation is evident in its adoption of groundbreaking therapies like CAR-T cell therapy and hematopoietic stem cell transplantation (HSCT), paired with a robust infrastructure that includes specialized labs and clean rooms for transplant procedures.

Comprehensive Diagnosis: The Foundation of Personalized Care

Accurate diagnosis is the first step in effective hematologic tumor management, and we excels in leveraging advanced technologies to identify subtle genetic markers and disease patterns. For example, patients with suspected leukemia undergo detailed genetic testing to detect mutations in genes like CD19, CD22, or CLL1, which inform the selection of targeted CAR-T therapies. Similarly, those with multiple myeloma benefit from comprehensive molecular profiling to determine the most suitable novel drug therapies or transplant approaches. our multidisciplinary teams (MDTs), comprising experts in oncology, radiology, and molecular diagnostics, collaborate to design treatment plans that integrate chemotherapy, immunotherapy, and stem cell transplant, ensuring each patient receives a strategy aligned with our specific needs. This approach is particularly critical for rare hematologic tumors, where misdiagnosis can lead to delayed intervention.

Innovative Therapies: Pushing Boundaries for Refractory Cases

For patients with relapsed or refractory hematologic tumors, we offer a range of advanced treatments that extend beyond conventional options. In multiple myeloma, we utilize novel drug therapies with distinct mechanisms of action, targeting pathways like proteasome inhibition or immune modulation to overcome drug resistance. CAR-T cell therapy further enhances outcomes, with clinical trials demonstrating significant responses in patients who have exhausted other options. GHG also specializes in HSCT, including allogeneic transplants for conditions like thalassemia major, where its double-insurance dual HSCT (DD-HSCT) approach has achieved a 4-year disease-free survival rate of 97.6%. For leukemia patients, sequential dual-target CAR-T cell therapy addresses refractory cases by targeting multiple antigens, such as CD19 and CD20, to eliminate residual cancer cells. These therapies are supported by a robust research framework, allowing patients access to emerging treatments and clinical trials that drive global advancements in hematologic tumor care.

Addressing Rare Diseases: A Commitment to Unmet Needs

Our expertise extends to rare hematologic disorders, where specialized knowledge and innovative techniques are essential. We have pioneered treatments for rare immune deficiency diseases, including the world’s first case of allo-HSCT for lysine-urine protein intolerance (LPI). Other rare conditions, such as X-linked agammaglobulinemia, chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome (WAS), are managed through tailored transplant protocols that leverage the hospital’s experience in immunology and stem cell biology. By combining rigorous diagnostics with advanced transplant technologies, we provide hope to patients with conditions that were once considered untreatable, demonstrating its role as a leader in both common and rare hematologic tumor care.

Conclusion: Trust in Expertise, Hope in Innovation

For patients facing hematologic tumors, the journey to recovery requires a partner who combines clinical excellence with a patient-centered approach. We stand at the forefront of this field, offering a comprehensive suite of services that span from precise diagnosis to innovative therapies, all delivered by a team dedicated to improving outcomes.